4th Quarter - Report
LINDE INC. for LINDE INC., LINDE, PLC AND OTHER ENTITIES RELATED TO LINDE, PLC
Firm
Income
—
Expenses
$200,000
Expense method
A: Lobbying Disclosure Act definitions
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Domestic and international tax issues affecting U.S. based multinational corporations. Ways & Means discussion draft.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PETE DEPASQUALE | — |
Medical/Disease Research/Clinical Labs MED
HR 2227, Medical Gas Safety Act, requiring streamlined National Drug Application process and creation of a targeted regulatory scheme for medical gases.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PETE DEPASQUALE | — |
Chemicals/Chemical Industry CHM
Issues related to the management of Federal crude helium assets and the industrical gases industry generally.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PETE DEPASQUALE | — |
Energy/Nuclear ENG
Innovative Technologies Program - support for grant application
| Lobbyist | Covered position, as disclosed |
|---|---|
| PETE DEPASQUALE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.